TXGHealthcare · Medical DevicesThe 19 Wall Street analysts covering 10X Genomics, Inc. hold a median 12-month price target of $70 — -4.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 14 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores 10X Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Volatility (35): The share price moves around a lot.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TXG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −4.2% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $40 → $70 |
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $47 → $70 |
| 12 Oct 2026 | Canaccord Genuity | Maintains | Buy | $60 → $100 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $52 → $110 |
| 29 Sept 2026 | Leerink Partners | Maintains | Market Perform | $40 → $90 |
| 29 Sept 2026 | Leerink Partners | Maintains | Market Perform | — |
| 28 Sept 2026 | Argus Research | Initiates | Buy | — |
| 28 Sept 2026 | Argus Research | Initiates | Buy | $110 |
| 28 Sept 2026 | Piper Sandler | Maintains | Neutral | — |
| 28 Sept 2026 | Piper Sandler | Maintains | Neutral | $47 → $80 |
| 9 Sept 2026 | UBS | Maintains | Neutral | $20 → $68 |
| 9 Sept 2026 | UBS | Maintains | Neutral | — |
| 1 Sept 2026 | RBC Capital | Initiates | Sector Perform | — |
| 1 Sept 2026 | RBC Capital | Initiates | Sector Perform | $70 |
| 12 Aug 2026 | Stephens & Co. | Maintains | Overweight | $50 → $65 |
| 12 Aug 2026 | Stephens & Co. | Maintains | Overweight | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $50 → $60 |
| 10 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 10 Aug 2026 | Piper Sandler | Maintains | Neutral | $42 → $47 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXG appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, 10X Genomics, Inc. returned +533.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 10% of US stocks
Cheaper than 8% of US stocks
Cheaper than 98% of US stocks
Higher than 14% of US stocks
Higher than 25% of US stocks
Higher than 87% of US stocks
Higher than 23% of US stocks
Higher than 19% of US stocks
Higher than 36% of US stocks
Higher than 32% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
10X Genomics, Inc. has a market value of $9.5B and an enterprise value of $9.1B.
Revenue in the twelve months to 30 June 2026: $616.9M. The latest quarter shrank 12.7% year on year.
Net income over the same four quarters: −$75.1M, a −12.2% net margin.
Diluted earnings per share, trailing twelve months: $−0.59.
Free cash flow in the twelve months to 30 June 2026: $121.4M.
Trailing P/E: −208.9×; forward P/E: 953.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
10X Genomics, Inc. employs 1,178 people — $524K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own 10X Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
10x Genomics announced it will report financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026.
Why it matters — TXG watchers can note the scheduled date for the company’s quarterly financial results announcement.
10x Genomics is partnering with Fred Hutchinson Cancer Center on cancer biomarker research, using single-cell and spatial technologies to advance precision oncology in two cancer types.
Why it matters — The collaboration highlights TXG’s single-cell and spatial technologies in cancer research with a major cancer center.
10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to apply single-cell and spatial technologies across solid tumors and blood cancers. Projects include bladder cancer biomarker discovery and residual disease detection in acute myeloid leukemia.
Why it matters — The collaboration highlights research applications of 10x Genomics’ technologies in cancer biomarker discovery and disease detection.
10x Genomics has begun shipping its Atera systems after receiving orders for over 40 systems, reflecting strong early demand and broad research interest in its spatial biology platform.
Why it matters — TXG watchers would care because initial order demand for the Atera platform suggests growing adoption of the company's spatial biology technology.
10x Genomics announced Sentira, a new cloud analysis platform that extends its workflow from data generation to experimental conclusions, starting with Sentira Spatial Analysis. The platform leverages NVIDIA accelerated computing to reduce spatial data processing times from hours to minutes.
Why it matters — For TXG watchers, this product announcement signals an expansion of 10x's offering beyond data generation into computational analysis, potentially strengthening its position in the spatial biology market.
The 19 Wall Street analysts covering 10X Genomics, Inc. have a median 12-month price target of $70, with estimates ranging from $50 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering 10X Genomics, Inc., 7 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 10X Genomics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, 10X Genomics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies -4.2% from the last close, and Ticker Nerd's factor model ranks 10X Genomics, Inc. 94 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering 10X Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $110 over the next 12 months.
10X Genomics, Inc. returned +533.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution.
The most recent item we track (PRNewsWire, 13 Oct 2026): "10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026". 10x Genomics announced it will report financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026.
10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution. The company develops integrated instruments, consumables, and software used for single-cell and spatial biology workflows, supporting applications such as gene expression analysis, immune profiling, chromatin accessibility, spatial transcriptomics, and in situ exploration of tissue biology. Its main product families include the Chromium platform, the Chromium X series, Visium, and Xenium, which are used by academic researchers, pharmaceutical companies, biotechnology firms, and other scientific organizations. 10x Genomics serves global markets across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. The stock is commonly associated with the broader life sciences tools and services sector, where the company plays a specialized role in enabling advanced biological research and data generation.
CEO Dr. Serge Saxonov Ph.D. · 1,178 employees · United States · https://www.10xgenomics.com
